Mapping of Treatment Patterns and Transfusion Status in Danish and Swedish Myelofibrosis (MF) Patients
Author(s)
Erik Ahlstrand, MD, PhD1, Christen Lykkegaard Andersen, MD, Professor2, Anna Ravn-Landtblom, MD, PhD3, Katja Nolvi, PhD cand4, Mathias Lilja, MSSc5, Morten Johnsen, MSc6, Lone Sander Dalsgaard, MSc Pharm7, Ami Albihn, PhD8.
1Örebro University Hospital, Örebro, Sweden, 2Rigshospitalet, Copenhagen, Denmark, 3Karolinska University Hospital, Stockholm, Sweden, 4Quantify Research, Helsinki, Finland, 5Quantify Research, Stockholm, Sweden, 6Quantify Research, Copenhagen, Denmark, 7GSK, Copenhagen, Denmark, 8GSK, Stockholm, Sweden.
1Örebro University Hospital, Örebro, Sweden, 2Rigshospitalet, Copenhagen, Denmark, 3Karolinska University Hospital, Stockholm, Sweden, 4Quantify Research, Helsinki, Finland, 5Quantify Research, Stockholm, Sweden, 6Quantify Research, Copenhagen, Denmark, 7GSK, Copenhagen, Denmark, 8GSK, Stockholm, Sweden.
OBJECTIVES: MF is a rare myeloproliferative neoplasm, currently incurable in most patients. Some therapies, including JAK inhibitors, may induce anaemia, which, in turn, potentially impairs prognosis. Consensus is lacking on how to manage treatment-related anaemia in Nordic countries. We collected real-world data on MF patients in Denmark and Sweden with the aim to assess treatment patterns (switches, dosage adjustments and transfusion requirements), associated outcomes and healthcare resource utilisation/costs for MF patients related to anaemia and transfusion status.
METHODS: Observational retrospective cohort study from Danish and Swedish quality registry data (2007-2022), including MF patients from 2012 onwards. Records for interventions and medication use were retrieved from hospital or prescription registries, and mortality data from causes of death registries. Patients were categorised as non-anaemic (Hb ≥12 g/dl), or anaemic with mild (10-<12 g/dl), moderate (8-<10 g/dl) or severe anaemia (<8 g/dl); and were defined as transfusion-dependent (TD), -requiring (TR) or -independent (TI).
RESULTS: Overall, 917 Danish MF patients (median age 72 y; 43% female) were included in the analysis, of whom 40% had anaemia and 12% received transfusions. MF incidence remained ~1.2/100,000 between 2012-2022, and prevalence 3.4-9.1/100,000. Additionally, 943 Swedish MF patients were included (median age 72 y; 44% female), of whom 51% had anaemia and 13% received transfusions. MF incidence was 0.6-1.1/100,000 between 2012-2022, and prevalence 1.9-5.2/100,000. For Swedish patients with mutation status available, mutations were: 52% JAK2, 4% MPL, 16% CALR and 1% other.
CONCLUSIONS: Preliminary results from our Danish-Swedish MF cohort suggest the prevalence of MF-related anaemia in both countries is slightly lower than expected. The high coverage, level of completeness and detail, and traceability of these registries will allow further analysis of treatment patterns, anaemia status, transfusion dependency, and clinical and economic outcomes. FUNDING: GSK (GSK study identifier 300275).
METHODS: Observational retrospective cohort study from Danish and Swedish quality registry data (2007-2022), including MF patients from 2012 onwards. Records for interventions and medication use were retrieved from hospital or prescription registries, and mortality data from causes of death registries. Patients were categorised as non-anaemic (Hb ≥12 g/dl), or anaemic with mild (10-<12 g/dl), moderate (8-<10 g/dl) or severe anaemia (<8 g/dl); and were defined as transfusion-dependent (TD), -requiring (TR) or -independent (TI).
RESULTS: Overall, 917 Danish MF patients (median age 72 y; 43% female) were included in the analysis, of whom 40% had anaemia and 12% received transfusions. MF incidence remained ~1.2/100,000 between 2012-2022, and prevalence 3.4-9.1/100,000. Additionally, 943 Swedish MF patients were included (median age 72 y; 44% female), of whom 51% had anaemia and 13% received transfusions. MF incidence was 0.6-1.1/100,000 between 2012-2022, and prevalence 1.9-5.2/100,000. For Swedish patients with mutation status available, mutations were: 52% JAK2, 4% MPL, 16% CALR and 1% other.
CONCLUSIONS: Preliminary results from our Danish-Swedish MF cohort suggest the prevalence of MF-related anaemia in both countries is slightly lower than expected. The high coverage, level of completeness and detail, and traceability of these registries will allow further analysis of treatment patterns, anaemia status, transfusion dependency, and clinical and economic outcomes. FUNDING: GSK (GSK study identifier 300275).
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH159
Topic
Epidemiology & Public Health
Disease
Oncology